NASH Target Development Service for Galectin 3 Inhibitors

As a leading service provider in drug development for NASH treatment, Creative Biolabs now provides professional Target Discovery and Therapeutic Strategies to support the growing interest in this field. We provide services focused on designing, developing, testing, and manufacturing galectin 3 inhibitors for NASH treatment.

Introduction of Galectin 3

Galectin 3 (Gal-3), belonging to the lectin family, is a protein that can specifically bind to beta-galactosides, suggesting a significant role in regulating cell adhesion, cell interaction, as well as the function of macrophage. Meanwhile, galectin 3 can be expressed in many portions of the cell, including the surface of cell, cytoplasm and cell nucleus. Pilot studies have demonstrated that the expression level of galectin 3 can determine the development of various diseases, such as certain tumors, fibrosis, and inflammatory diseases. A novel study has suggested that the high level of galectin 3 can cause the incidence and process of various fibrosis, including idiopathic pulmonary fibrosis (IPF), renal, or liver fibrosis. As a result, many scientists are all dedicating to developing new methods for blocking the function of galectin 3, and then a series of galectin 3 inhibitors have been generated and have been widely used for galectin related disease therapy, like fibrosis, heart disease, and cancers.

Fig.1 The structure of Galectin 3.

Our Platform for Galectin 3 Inhibitors

Galectin 3 has been considered as an attractive target for a full range of diseases and its inhibitors have been designed and tested for a large scale of preclinical studies. In general, the strategies for galectin 3 inhibitor generation are based on the function of Gal-3 non-carbohydrate or carbohydrate receptor. Therefore, Creative Biolabs has established a panel of assays for discovering Gal-3 inhibitors for NASH treatment basing on our advanced technologies. Currently, we can provide a seamless of services on different types of inhibitors design, modification, safety, and efficacy evaluation. The peptide-derived inhibitors are the most commonly used inhibitors in our platform. For instance, a peptide-derived inhibitor (G3-C12) can specifically bind to Gal-3 and increase the efficacy of 5-fluorouracil (5-FU) against various cancer cells. In addition, we also offer the services of several polysaccharide-based Gal-3 inhibitors and small-molecule carbohydrate-based Gal-3 inhibitors, such as GM-CT-01, GR-MD-02. The binding affinity and the efficacy of these inhibitors can be further analyzed by our professional staff, which will provide reliable data for your NASH projects.

Fig.2 The profibrotic network of Gal-3 secreted by macrophages and fibroblasts in tissue fibrosis. (Li, 2014)

As one of the top CROs in the field of drug development for NASH therapy, Creative Biolabs has focused on the treatment of NASH therapies for years and has successfully accomplished numerous challenging projects in this field. We can offer high-quality target construction and custom services of galectin 3 inhibitors for our clients. If you are interested in our services, please contact us or send us an inquiry.

Reference

1. Li, L.C.; et al. Functions of Galectin-3 and Its Role in Fibrotic Diseases. J Pharmacol Exp Ther. 2014, 351(2): 336-43.